Literature DB >> 7907952

Taxol and taxotere in bladder cancer: in vitro activity and urine stability.

C Rangel1, H Niell, A Miller, C Cox.   

Abstract

In this study the antimicrotubular agents taxol, taxotere, and vinblastine were compared for their ability to inhibit the clonal growth of human bladder tumor cell lines using a soft-agar clonogenic assay. The stability of taxol and taxotere was evaluated by high-performance liquid chromatography over a range of pH in human urine. Both taxol and taxotere were shown to maximally inhibit the clonal growth of human bladder cell lines within 1 h of drug incubation. The most active agent in the panel of tumor lines was taxotere, with 6 of 12 lines being sensitive to the agent at 0.01 microM and all cell lines being sensitive at 0.1 microM. Taxol was active in 1 of 12 lines at 0.01 microM and in 11 of 12 at 0.1 microM. Only 2 of 12 cell lines were sensitive to vinblastine over the 0.01- to 0.1-microM dose range. Taxol and taxotere were found to be stable in human urine for 4 h over a pH range of 5-7. At least 85% of both drugs were present during this period of drug incubation. Our findings suggest that both taxol and taxotere may be clinically useful agents for systemic and intravesical use in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907952     DOI: 10.1007/bf00686501

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

Review 1.  Taxol: an antimitotic agent with a new mechanism of action.

Authors:  J J Manfredi; S B Horwitz
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

2.  Primary bioassay of human myeloma stem cells.

Authors:  A Hamburger; S E Salmon
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

3.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

Authors:  M C Bissery; D Guénard; F Guéritte-Voegelein; F Lavelle
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

4.  Relationships between the structure of taxol analogues and their antimitotic activity.

Authors:  F Guéritte-Voegelein; D Guénard; F Lavelle; M T Le Goff; L Mangatal; P Potier
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

5.  Anticancer drug activity in human bladder tumor cell lines.

Authors:  H B Niell; K C Webster; E E Smith
Journal:  Cancer       Date:  1985-09-01       Impact factor: 6.860

6.  Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors.

Authors:  M S Blumenreich; A Yagoda; R B Natale; R C Watson
Journal:  Cancer       Date:  1982-08-01       Impact factor: 6.860

7.  Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium.

Authors:  I Ringel; S B Horwitz
Journal:  J Pharmacol Exp Ther       Date:  1987-08       Impact factor: 4.030

8.  Phase I clinical and pharmacokinetic study of taxol.

Authors:  P H Wiernik; E L Schwartz; J J Strauman; J P Dutcher; R B Lipton; E Paietta
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

9.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.

Authors:  S M Longnecker; R C Donehower; A E Cates; T L Chen; R B Brundrett; L B Grochow; D S Ettinger; M Colvin
Journal:  Cancer Treat Rep       Date:  1987-01
View more
  9 in total

Review 1.  New therapies for non-muscle-invasive bladder cancer.

Authors:  Edmund Chiong; Kesavan Esuvaranathan
Journal:  World J Urol       Date:  2009-09-18       Impact factor: 4.226

Review 2.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

3.  Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells.

Authors:  Sangchul Lee; Kwangtaek Kim; Jin-Nyoung Ho; Hyunjin Jin; Seok-Soo Byun; Eunsik Lee
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

4.  Characterization of lipid droplets from a Taxus media cell suspension and their potential involvement in trafficking and secretion of paclitaxel.

Authors:  Abdulsamie Hanano; Edgar Perez-Matas; Mouhnad Shaban; Rosa M Cusido; Denis J Murphy
Journal:  Plant Cell Rep       Date:  2022-01-04       Impact factor: 4.570

5.  Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.

Authors:  D Papamichael; C J Gallagher; R T Oliver; P W Johnson; J Waxman
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy.

Authors:  Melissa A Laudano; Lamont J Barlow; Alana M Murphy; Daniel P Petrylak; Manisha Desai; Mitchell C Benson; James M McKiernan
Journal:  Urology       Date:  2009-11-13       Impact factor: 2.649

Review 7.  Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning.

Authors:  Kelly Ward; Mark O Kitchen; Suresh-Jay Mathias; Farhat L Khanim; Richard T Bryan
Journal:  Front Surg       Date:  2022-07-26

8.  Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.

Authors:  C C Zielinski; B Schnack; M Grbovic; T Brodowicz; C Wiltschke; G Steger; H Pflüger; M Marberger
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

Review 9.  Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.

Authors:  Jeffrey J Tomaszewski; Marc C Smaldone
Journal:  Open Access J Urol       Date:  2010-05-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.